A Clinical Study Evaluating the Efficacy of Systemic Chemotherapy and Immune Checkpoint Inhibitors Combined With Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer Patients With Peritoneal Metastasis

PHASE2RecruitingINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

February 15, 2025

Primary Completion Date

July 31, 2027

Study Completion Date

December 31, 2027

Conditions
Gastric Cancer
Interventions
DRUG

HIPEC

HIPEC treatment (Oxaliplatin, physiological saline at 43°C for 60 min) was performed after the Laparoscopic exploratory surgery.

DRUG

SOX

Oxaliplatin, 130 mg, i.v. + S-1 (40 mg per dose for BSA \<1.25; 60 mg per dose for BSA 1.25 to 1.5; 60 mg per dose for BSA ≥1.5, twice daily for each treatment cycle d1-14, q3w

DRUG

Immune Checkpoint Inhibitors

Tislelizumab, 200 mg, q3w

Trial Locations (1)

430022

RECRUITING

Wuhan Union Hospital, Wuhan

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

BeiGene

INDUSTRY

lead

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER

NCT06685887 - A Clinical Study Evaluating the Efficacy of Systemic Chemotherapy and Immune Checkpoint Inhibitors Combined With Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer Patients With Peritoneal Metastasis | Biotech Hunter | Biotech Hunter